Bionexus Gene Lab Stock Analysis

BioNexus Stock Analysis Notes

About 44.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.56. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioNexus Gene Lab has Price/Earnings (P/E) ratio of 350.0. The entity recorded a loss per share of 0.06. The firm had not issued any dividends in recent years. BioNexus Gene had 1:12 split on the 20th of July 2023. BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diagnostic tests for the early detection of diseases and personalized health management primarily in Malaysia. BioNexus Gene Lab Corporation was incorporated in 2017 and is based in Kuala Lumpur, Malaysia with an additional office in Sheridan, Wyoming. Bionexus Gene operates under Diagnostics Research classification in the United States and is traded on OTC Exchange. It employs 27 people. For more info on BioNexus Gene Lab please contact Sook Yeoh at 60 1 307 241 6898 or go to https://www.bionexusgenelab.com.

BioNexus Gene Lab Investment Alerts

BioNexus Gene Lab Upcoming and Recent Events

BioNexus Market Capitalization

The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.23 M.

BioNexus Profitablity

The company has Profit Margin (PM) of (0.24) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.

Management Efficiency

BioNexus Gene Lab has return on total asset (ROA) of (0.1011) % which means that it has lost $0.1011 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2844) %, meaning that it created substantial loss on money invested by shareholders. BioNexus Gene's management efficiency ratios could be used to measure how well BioNexus Gene manages its routine affairs as well as how well it operates its assets and liabilities. As of November 26, 2024, Return On Tangible Assets is expected to decline to -0.24. The current year's Return On Capital Employed is expected to grow to -0.25. The current year's Net Tangible Assets is expected to grow to about 8.7 M, whereas Total Current Assets are forecasted to decline to about 4.5 M.

Technical Drivers

As of the 26th of November, BioNexus Gene shows the Risk Adjusted Performance of (0.10), mean deviation of 2.69, and Standard Deviation of 3.49. BioNexus Gene Lab technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

BioNexus Gene Lab Price Movement Analysis

BioNexus Gene Lab Insider Trading Activities

BioNexus Gene Predictive Daily Indicators

BioNexus Gene Forecast Models

BioNexus Gene's time-series forecasting models are one of many BioNexus Gene's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioNexus Gene's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how BioNexus Gene prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioNexus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioNexus Gene. By using and applying BioNexus Stock analysis, traders can create a robust methodology for identifying BioNexus entry and exit points for their positions.

When running BioNexus Gene's price analysis, check to measure BioNexus Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNexus Gene is operating at the current time. Most of BioNexus Gene's value examination focuses on studying past and present price action to predict the probability of BioNexus Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNexus Gene's price. Additionally, you may evaluate how the addition of BioNexus Gene to your portfolios can decrease your overall portfolio volatility.